Form D · Biotechnology
Swep Bio, Inc.
Scarsdale, NY · CIK 0002159106
Offering snapshot reported Oct 29, 2026 · SEC filing
- Reported sold
- $2.5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 28, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2026 | Initial | $2,499,989 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-602899
Source: Form D, filed Oct 29, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lovisa Backemar | Director |
| Karl Erik Emanuel Berglund | Director, Executive |
| Goran Mikael Dolsten | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7 Rochambeau Road
Scarsdale, NY, 10583
Scarsdale, NY, 10583